BCM
CALA

Bayesian Capital Management’s Calithera Biosciences, Inc CALA Stock Holding History

Bayesian Capital Management’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,000
Closed -$48K – 715
2021
Q1 		$48K Buy
+1,000
New +$58.2K 0.01% 508

Other funds holding CALA

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bayesian Capital Management's CALA Position: Q2 2021 in Review

Bayesian Capital Management sold out of Calithera Biosciences, Inc (CALA) in Q2 2021, closing a stake of 1,000 shares — an estimated $48K sold.

Bayesian Capital Management first reported a position in CALA in Q1 2021 and held it in 1 quarter. The position peaked at $48K in Q1 2021. 76 funds tracked by Wall St. Rank hold CALA as of Q2 2021.

  • Bayesian Capital Management reported no remaining Calithera Biosciences, Inc position as of Q2 2021 after selling out during the quarter.
  • Bayesian Capital Management sold 1,000 Calithera Biosciences, Inc shares in Q2 2021, an estimated $48K.
  • Bayesian Capital Management first reported a position in Calithera Biosciences, Inc in Q1 2021 and held it in 1 quarter.
  • Bayesian Capital Management's Calithera Biosciences, Inc position peaked at $48K in Q1 2021.
  • 76 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q2 2021.

Based on Bayesian Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.